Home' Australian Pharmacist : Australian Pharmacist February 2015 Contents Australian Pharmacist February 2015 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
KEY LEARNING POINTS
• The prevalence of OSA is high and
places considerable demand on health
• Pharmacists have the potential to
become a valuable member of the
sleep health team and provide OSA
services in community pharmacies.
• Collaborative approaches to care are
important in achieving optimal patient
1. Kryger MH, Roth T, Dement WC. Principles and practice of
sleep medicine. 5th edn. Philadelphia, PA: Saunders/Elsevier;
2. Malhotra A, White DP. Obstructive sleep apnoea. Lancet
3. American Academy of Sleep Medicine Task Force. Sleep-
related breathing disorders in adults: Recommendations for
syndrome definition and measurement techniques in clinical
research. Sleep 1999;22:662–89.
4. Engleman H, Douglas N. Sleep·4: Sleepiness, cognitive
function, and quality of life in obstructive sleep apnoea/
hypopnoea syndrome. Thorax 2004;59:618–22 .
5. Tregear S, Reston J, Schoelles K, et al. Obstructive sleep apnea
and risk of motor vehicle crash: systematic review and meta-
analysis. J Clin Sleep Med 2009;5:573–81.
6. Marshall N, Wong K, Liu P, et al. Sleep apnea as an
independent risk factor for all-cause mortality: the Busselton
health study. Sleep 2008;31:1079–85.
7. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular
outcomes in men with obstructive sleep apnoea-hypopnoea
with or without treatment with continuous positive airway
pressure: an observational study. Lancet 2005;365:1046–53.
8. Young T, Peppard PE, Gottlieb DJ. Epidemiology of
obstructive sleep apnea: a population health perspective. Am
J Respir Crit Care Med 2002;165:1217–39.
9. Young T, Peppard PE, Taheri S. Excess weight and sleep-
disordered breathing. J Appl Physiol 2005;99:1592–9 .
10. Peppard PE, Young T, Barnet JH, et al. Increased prevalence
of sleep-disordered breathing in adults. Am J Epidemiol
11. Young T, Evans L, Finn L, et al. Estimation of the clinically
diagnosed proportion of sleep apnea syndrome in middle-
aged men and women. Sleep 1997;20:705–6 .
12. Deloitte Access Economics. Re-awakening Australia: The
economic cost of sleep disorders in Australia, 2010. Canberra,
Australia: Deloitte Access Economics; 2011. At: www.
13. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the
evaluation, management and long-term care of obstructive
sleep apnea in adults. J Clin Sleep Med 2009;5:263–76.
14. Giles TL, Lasserson TJ, Smith B, et al. Continuous positive
air ways pressure for obstructive sleep apnoea in adults.
Cochrane Database of Systematic Reviews 2006, Issue 3. Art.
No.: CD001106. DOI: 10.1002/14651858.CD001106.pub3.
15. Montserrat JM, Ferrer M, Hernandez L, et al. Effectiveness
of CPAP treatment in daytime function in sleep apnea
syndrome: a randomized controlled study with an optimized
placebo. Am J Respir Crit Care Med 2001;164:608–13.
16. Jenkinson C, Davies RJ, Mullins R, et al. Comparison of
therapeutic and subtherapeutic nasal continuous positive
air way pressure for obstructive sleep apnoea: a randomised
prospective parallel trial. Lancet 1999;353:2100–5.
17. Ballester E, Badia JR, Hernandez L, et al. Evidence of the
effectiveness of continuous positive airway pressure in the
treatment of sleep apnea/hypopnea syndrome. Am J Respir
Crit Care Med 1999;159:495–501.
18. Loredo JS, Ancoli-Israel S, Dimsdale JE. Effect of continuous
positive airway pressure vs placebo continuous positive
air way pressure on sleep quality in obstructive sleep apnea.
CHEST 1999;116:1545–9 .
19. Kakkar RK, Berry RB. Positive airway pressure treatment for
obstructive sleep apnea. CHEST 2007;132:1057–72.
20. Gay P, Weaver T, Loube D, et al. Evaluation of positive airway
pressure treatment for sleep related breathing disorders in
adults. Sleep 2006;29:381–401.
21. Weaver TE, Grunstein RR. Adherence to continuous positive
air way pressure therapy: the challenge to effective treatment.
Proceedings of the American Thoracic Society 2008;5:173–8 .
22. Mansfield DR, Antic NA, McEvoy RD. How to assess, diagnose,
refer and treat adult obstructive sleep apnoea: a commentary
on the choices. Med J Aust 2013;199:S21–S6.
23. Adams RJ, Piantadosi C, Appleton SL, et al. Investigating
obstructive sleep apnoea: will the health system have the
capacity to cope? A population study. Aust Health Rev
24. Flemons WW, Douglas NJ, Kuna ST, et al. Access to diagnosis
and treatment of patients with suspected sleep apnea. Am J
Respir Crit Care Med 2004;169:668–72.
25. Chai-Coetzer CL, Antic NA, Rowland LS, et al. Primary care
vs specialist sleep center management of obstructive
sleep apnea and daytime sleepiness and quality of life: A
randomized trial. JAMA 2013;309:997–1004.
26. Chai-Coetzer CL, Antic NA, Rowland LS, et al. A simplified
model of screening questionnaire and home monitoring
for obstructive sleep apnoea in primary care. Thorax
27. Antic NA, Buchan C, Esterman A, et al. A randomized
controlled trial of nurse-led care for symptomatic moderate–
severe obstructive sleep apnea. Am J Respir Crit Care Med
28. Tran A, Fuller J, Wong K, et al. The development of a sleep
disorder screening program in Australian community
pharmacies. Pharm World Sci 2009;31:473–80.
29. Schwegler K, Klaghofer R, Nirkko AC, et al. Sleep and
wakefulness disturbances in Swiss pharmacy customers.
Swiss Med Wkly 2006;136:149–54.
30. Perraudin C, Le Vaillant M, Pelletier-Fleury N. Cost-
effectiveness of a community pharmacist-led sleep
apnea screening program–a Markov model. PloS one
31. Kashyap KC, Nissen LM, Smith SS, et al. Can a community
pharmacy sleep assessment tool aid the identification of
patients at risk of sleep disorders in the community: a pilot
study. Integrated Pharmacy Research and Practice 2012;1:3–12.
32. Hersberger KE, Renggli VP, Nirkko AC, et al. Screening for
sleep disorders in community pharmacies – evaluation of a
campaign in Switzerland. J Clin Pharm Ther 2006;31:35–41.
33. Fuller JM, Wong KK, Krass I, et al. Sleep disorders screening,
sleep health awareness, and patient follow-up by community
pharmacists in Australia. Patient Educ Couns 2011;83:325–35.
34. Fuller JM, Wong KK, Grunstein R, et al. A comparison
of screening methods for sleep disorders in Australian
community pharmacies: A randomized controlled trial. PloS
35. Hanes CA, Wong KK, Saini B. Clinical services for obstructive
sleep apnea patients in pharmacies: the Australian experience.
Int J Clin Pharm 2014;36:460–8.
36. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin
Questionnaire to identify patients at risk for the sleep apnea
syndrome. Ann Intern Med 1999;131:485–91.
37. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire:
a tool to screen patients for obstructive sleep apnea.
38. Johns MW. A new method for measuring daytime sleepiness:
the Epworth sleepiness scale. Sleep 1991;14:540–5.
39. Hanes CA, Wong KK, Saini B. A model of care for Australian
community pharmacies providing obstructive sleep apnea
ser vices (Research report), Version 1.0. Sydney, NSW: Faculty of
Pharmacy, The University of Sydney; April 2014.
40. Sawyer AM, Gooneratne NS, Marcus CL, et al. A systematic
review of CPAP adherence across age groups: clinical and
empiric insights for developing CPAP adherence inter ventions.
Sleep Med Rev 2011;15:343–56.
41. Australasian Sleep Association. Position Paper: Best Practice
Guidelines for Provision of CPAP Therapy; 2009. At: www.sleep.
42. Popescu G, Latham M, Allgar V, et al. Continuous positive
airway pressure for sleep apnoea/hypopnoea syndrome:
usefulness of a 2 week trial to identify factors associated with
long term use. Thorax 2001;56:727–33 .
43. Lewis KE, Seale L, Bartle IE, et al. Early predictors of CPAP use for
the treatment of obstructive sleep apnea. Sleep 2004;27:134–8.
44. Hanes CA, Wong KK, Saini B. Consolidating innovative practice
models: The case for obstructive sleep apnea services in
Australian pharmacies. Research in Social and Administrative
Pharmacy 2014;doi: 10.1016/j.sapharm.2014.08.009.
45. Wolkove N, Baltzan M, Kamel H, et al. Long-term compliance
with continuous positive airway pressure in patients with
obstructive sleep apnea. Can Respir J 2008;15:365–9.
46. Hanes CA, Wong KK, Saini B. An overview of service quality
of continuous positive airway pressure services in Australian
pharmacies. Respirology 2014;19:85–91.
47. Chai-Coetzer CL, Douglas J, McEvoy D, et al. Guidelines
for sleep studies in adults. Prepared for the Australasian
Sleep Association; 2014. At: www.sleep.org.au/documents/
48. Young T, Palta M, Dempsey J, et al. Burden of sleep apnea:
rationale, design, and major findings of the Wisconsin Sleep
Cohort study. WMJ: official publication of the State Medical
Society of Wisconsin 2009;108:246–49.
1. Untreated OSA is associated with an
increased risk of:
a) Stroke, constipation, hypertension,
b) Hypertension, stroke, motor vehicle
c) Psychosis, hypertension, mortality,
d) Stroke, motor vehicle accidents, road
2. Treatment options for OSA include:
a) Surgery, sleeping in the supine position,
b) Weight loss, mandibular advancement
splints, negative airway pressure.
c) Mandibular advancement splints,
surgery, positive airway pressure.
d) Sleeping in the supine position, positive
airway pressure, weight loss.
3. Screening tools can assist with the
identification of risk factors for OSA.
Which of the following is NOT a risk
factor for OSA?
b) Male gender.
c) Witnessed apnoeas.
d) Chest circumference.
4. CPAP adherence patterns are
thought to be established within
which period of time after
a) The first hour.
b) The first day.
c) The first week.
d) The first year.
Links Archive Australian Pharmacist January 2015 Australian Pharmacist March 2015 Navigation Previous Page Next Page